Compile Data Set for Download or QSAR
Report error Found 271 Enz. Inhib. hit(s) with all data for entry = 133
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187100(US9670157, 114 3-Methyl-1-[4-(4-methyl-pyrazol-1-y...)
Affinity DataIC50: 0.600nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187097(US9670157, 111 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187104(US9670157, 118 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 1nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187092(US9670157, 106 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187098(US9670157, 112 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187099(US9670157, 113 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187110(US9670157, 124 3-Methyl-1-(2-methyl-quinolin-6-ylm...)
Affinity DataIC50: 2nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187093(US9670157, 107 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187111(US9670157, 125 5-Methyl-1-(2-methyl-quinolin-6-ylm...)
Affinity DataIC50: 3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187112(US9670157, 126 1-(2-Methyl-quinolin-6-ylmethyl)-3-...)
Affinity DataIC50: 3nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187087(US9670157, 101 2,5-Dimethyl-1-[4-(4-methyl-pyrazol...)
Affinity DataIC50: 4nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187095(US9670157, 109 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 5nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186837(US9670157, 3 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50: 6nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186920(US9670157, 86 1-[4-(3,5-Dimethyl-pyrazol-1-ylmethy...)
Affinity DataIC50: 7nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187097(US9670157, 111 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 8nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187105(US9670157, 119 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 9nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186919(US9670157, 85 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-b...)
Affinity DataIC50: 11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186952(US9670157, 94 2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-...)
Affinity DataIC50: 11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187088(US9670157, 102 1-Ethyl-4-methyl-5-[4-(4-methyl-pyr...)
Affinity DataIC50: 11nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186836(US9670157, 2 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50: 15nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186954(US9670157, 95 1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyri...)
Affinity DataIC50: 16nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187115(US9670157, 129 1-(2-Pyrrolidin-1-yl-pyridin-4-ylme...)
Affinity DataIC50: 24nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186956(US9670157, 97 2,5-Dimethyl-1-[4-(4-methyl-pyrazol-...)
Affinity DataIC50: 28nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186949(US9670157, 91 2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-...)
Affinity DataIC50: 29nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186888(US9670157, 54 2,5-Dimethyl-1-(2-phenyl-thiazol-4-y...)
Affinity DataIC50: 30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187090(US9670157, 104 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 30nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187094(US9670157, 108 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 33nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186959(US9670157, 99 1-Ethyl-4-methyl-5-[4-(4-methyl-pyra...)
Affinity DataIC50: 38nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186950(US9670157, 92 1-Ethyl-4-methyl-5-[4-(2-oxo-2H-pyri...)
Affinity DataIC50: 40nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187103(US9670157, 117 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-...)
Affinity DataIC50: 51nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186884(US9670157, 50 2,5-Dimethyl-1-(2-phenyl-thiazol-4-y...)
Affinity DataIC50: 56nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186835(US9670157, 1 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50: 63nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186955(US9670157, 96 2,5-Dimethyl-1-[4-(4-methyl-pyrazol-...)
Affinity DataIC50: 63nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186881(US9670157, 47 2,5-Dimethyl-1-(2-phenyl-thiazol-4-y...)
Affinity DataIC50: 74nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186883(US9670157, 49 2,5-Dimethyl-1-(2-phenyl-thiazol-4-y...)
Affinity DataIC50: 89nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186948(US9670157, 90 2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-...)
Affinity DataIC50: 114nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186838(US9670157, 4 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50: 121nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186879(US9670157, 45 2,5-Dimethyl-1-(2-phenyl-thiazol-4-y...)
Affinity DataIC50: 135nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186863(US9670157, 29 1-[2-(3-Fluoro-phenyl)-thiazol-4-ylm...)
Affinity DataIC50: 140nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187107(US9670157, 121 1-Ethyl-4-methyl-5-[4-(4-methyl-pyr...)
Affinity DataIC50: 151nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187107(US9670157, 121 1-Ethyl-4-methyl-5-[4-(4-methyl-pyr...)
Affinity DataIC50: 155nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186871(US9670157, 37 2,5-Dimethyl-1-(2-thiophen-3-yl-thia...)
Affinity DataIC50: 170nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186850(US9670157, 16 2,5-Dimethyl-1-(6-phenyl-pyridin-2-y...)
Affinity DataIC50: 186nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186877(US9670157, 43 2,5-Dimethyl-1-(2-phenyl-thiazol-4-y...)
Affinity DataIC50: 196nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186870(US9670157, 36 2,5-Dimethyl-1-(2-pyridin-2-yl-thiaz...)
Affinity DataIC50: 203nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186947(US9670157, 89 1-[4-(2-Oxo-2H-pyridin-1-ylmethyl)-b...)
Affinity DataIC50: 226nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186865(US9670157, 31 2,5-Dimethyl-1-(2-pyridin-3-yl-thiaz...)
Affinity DataIC50: 251nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetKallikrein-1(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM187110(US9670157, 124 3-Methyl-1-(2-methyl-quinolin-6-ylm...)
Affinity DataIC50: 301nMAssay Description:KLK1 inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8, 185; Shori ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186885(US9670157, 51 2,5-Dimethyl-1-(2-phenyl-thiazol-4-y...)
Affinity DataIC50: 341nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

US Patent
LigandPNGBDBM186842(US9670157, 8 2,5-Dimethyl-1-(5-pyridin-3-yl-thioph...)
Affinity DataIC50: 348nMAssay Description:Plasma kallikrein inhibitory activity in vitro was determined using standard published methods (see e.g. Johansen et al., Int. J. Tiss. Reac. 1986, 8...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/19/2018
Entry Details
Go to US Patent

Displayed 1 to 50 (of 271 total ) | Next | Last >>
Jump to: